Cardlytics Stock Performance
| CDLX Stock | USD 1.78 0.01 0.56% |
On a scale of 0 to 100, Cardlytics holds a performance score of 6. The firm shows a Beta (market volatility) of 2.17, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardlytics will likely underperform. Please check Cardlytics' maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to make a quick decision on whether Cardlytics' price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cardlytics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Cardlytics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of 682 shares by Lynton Nicholas Hollmeyer of Cardlytics subject to Rule 16b-3 | 04/17/2025 |
2 | TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners | 04/30/2025 |
3 | Q1 2025 Cardlytics Inc Earnings Call Transcript | 05/08/2025 |
4 | Cardlytics First Quarter 2025 Earnings Beats Expectations | 05/09/2025 |
5 | Disposition of 43750 shares by Alexis DeSieno of Cardlytics subject to Rule 16b-3 | 05/14/2025 |
6 | Disposition of 26217 shares by Alexis DeSieno of Cardlytics at 1.938 subject to Rule 16b-3 | 05/15/2025 |
7 | Cardlytics Launches New Rewards Platform for Enhanced Customer Loyalty CDLX Stock News | 05/20/2025 |
8 | Disposition of 11000 shares by Fernandez Andre J of Cardlytics subject to Rule 16b-3 | 05/23/2025 |
9 | 144,238 Shares in Cardlytics, Inc. Bought by Millennium Management LLC - MarketBeat | 06/09/2025 |
10 | Acquisition by Amit Gupta of 300000 shares of Cardlytics subject to Rule 16b-3 | 06/23/2025 |
11 | Disposition of 581 shares by Lynton Nicholas Hollmeyer of Cardlytics subject to Rule 16b-3 | 07/01/2025 |
12 | Disposition of 5271 shares by Lynton Nicholas Hollmeyer of Cardlytics at 1.7826 subject to Rule 16b-3 | 07/02/2025 |
13 | Cardlytics amends agreement with JPMorgan Chase, extends term to 2028 By Investing.com - Investing.com Canada | 07/08/2025 |
| Begin Period Cash Flow | 91.8 M |
Cardlytics | Build AI portfolio with Cardlytics Stock |
Cardlytics Relative Risk vs. Return Landscape
If you would invest 141.00 in Cardlytics on April 13, 2025 and sell it today you would earn a total of 37.00 from holding Cardlytics or generate 26.24% return on investment over 90 days. Cardlytics is currently generating 0.5732% in daily expected returns and assumes 6.5087% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Cardlytics, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cardlytics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardlytics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cardlytics, and traders can use it to determine the average amount a Cardlytics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0881
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CDLX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.51 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.57 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Cardlytics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cardlytics by adding it to a well-diversified portfolio.
Cardlytics Fundamentals Growth
Cardlytics Stock prices reflect investors' perceptions of the future prospects and financial health of Cardlytics, and Cardlytics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cardlytics Stock performance.
| Return On Equity | -1.35 | ||||
| Return On Asset | -0.0878 | ||||
| Profit Margin | (0.65) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 262.13 M | ||||
| Shares Outstanding | 52.5 M | ||||
| Price To Earning | (3.47) X | ||||
| Price To Book | 1.46 X | ||||
| Price To Sales | 0.34 X | ||||
| Revenue | 278.3 M | ||||
| Gross Profit | 115.16 M | ||||
| EBITDA | (152.53 M) | ||||
| Net Income | (189.3 M) | ||||
| Cash And Equivalents | 157.04 M | ||||
| Cash Per Share | 4.77 X | ||||
| Total Debt | 221.65 M | ||||
| Debt To Equity | 0.42 % | ||||
| Current Ratio | 0.90 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (8.82 M) | ||||
| Earnings Per Share | (3.59) X | ||||
| Market Capitalization | 93.98 M | ||||
| Total Asset | 392.71 M | ||||
| Retained Earnings | (1.3 B) | ||||
| Working Capital | 29.03 M | ||||
| Current Asset | 81.93 M | ||||
| Current Liabilities | 52.77 M | ||||
About Cardlytics Performance
Evaluating Cardlytics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cardlytics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cardlytics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.18 | 0.17 | |
| Return On Tangible Assets | (0.85) | (0.90) | |
| Return On Capital Employed | (0.80) | (0.84) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (2.70) | (2.57) |
Things to note about Cardlytics performance evaluation
Checking the ongoing alerts about Cardlytics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cardlytics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cardlytics is way too risky over 90 days horizon | |
| Cardlytics may become a speculative penny stock | |
| Cardlytics appears to be risky and price may revert if volatility continues | |
| Cardlytics has high likelihood to experience some financial distress in the next 2 years | |
| Cardlytics currently holds 221.65 M in liabilities with Debt to Equity (D/E) ratio of 0.42, which is about average as compared to similar companies. Cardlytics has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Cardlytics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 278.3 M. Net Loss for the year was (189.3 M) with profit before overhead, payroll, taxes, and interest of 115.16 M. | |
| Cardlytics currently holds about 157.04 M in cash with (8.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Cardlytics amends agreement with JPMorgan Chase, extends term to 2028 By Investing.com - Investing.com Canada |
- Analyzing Cardlytics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cardlytics' stock is overvalued or undervalued compared to its peers.
- Examining Cardlytics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cardlytics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cardlytics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cardlytics' stock. These opinions can provide insight into Cardlytics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cardlytics Stock Analysis
When running Cardlytics' price analysis, check to measure Cardlytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardlytics is operating at the current time. Most of Cardlytics' value examination focuses on studying past and present price action to predict the probability of Cardlytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardlytics' price. Additionally, you may evaluate how the addition of Cardlytics to your portfolios can decrease your overall portfolio volatility.